Q-omics provides the consensus-scored MYCN profile across patient tissues and cancer cell-line models. MYCN expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MYCN is differentially expressed in 15, with the highest sampling consensus in KIRP. Additionally, MYCN RNA expression shows 18,586 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KIRP, and UVM as cancer lineages where MYCN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYCN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYCN survival associations across molecular data types. MYCN RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYCN RNA expression–survival associations across cancer types. High MYCN expression shows unfavorable associations in UVM and MESO, but favorable associations in KIRC, HNSC, UCS and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MYCN RNA expression.
This table summarizes MYCN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for MYCN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYCN shows lower tumor expression in KIRP, THCA, KIRC and KICH and higher tumor expression in BLCA and LIHC. The KIRP box plot shows higher MYCN RNA expression in normal versus tumor tissue (log2 FC = −2.410, t-test p < 0.001).
This table shows molecular features associated with MYCN in patient tissues and cancer cell lines. In patient samples, MYCN shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MYCN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BONE.
